A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects

Trial Profile

A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Galidesivir (Primary)
  • Indications Ebola virus infections; Marburg virus disease; Middle East respiratory syndrome coronavirus; Yellow fever
  • Focus Adverse reactions; First in man
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 05 May 2016 Status changed from recruiting to completed, as per BioCryst media release.
    • 08 May 2015 According to Biocryst media release, safety and pharmacokinetic/phamacodynamic results from this trial are expected in the third quarter of 2015.
    • 08 May 2015 According to Biocryst media release, this trial is funded by NIAID.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top